Radiat Oncol J.  2014 Sep;32(3):125-131. 10.3857/roj.2014.32.3.125.

Postoperative radiotherapy in salivary ductal carcinoma: a single institution experience

• Kim TH
• Kim MS
• Choi SH
• Suh YG
• Koh YW
• Kim SH
• Choi EC
• Keum KC

• KMID: 2316726
• DOI: http://doi.org/10.3857/roj.2014.32.3.125

Abstract

PURPOSE
We reviewed treatment outcomes and prognostic factors for patients with salivary ductal carcinoma (SDC) treated with surgery and postoperative radiotherapy from 2005 to 2012.
MATERIALS AND METHODS
A total of 16 patients were identified and 15 eligible patients were included in analysis. Median age was 61 years (range, 40 to 71 years) and 12 patients (80%) were men. Twelve patients (80%) had a tumor in the parotid gland, 9 (60%) had T3 or T4 disease, and 9 (60%) had positive nodal disease. All patients underwent surgery and postoperative radiotherapy. Postoperative radiotherapy was delivered using 3-dimensional conformal radiotherapy or intensity-modulated radiotherapy. Locoregional failure-free survival (LRFFS), distant failure-free survival (DFFS), progression-free survival (PFS), and overall survival (OS) were calculated using the Kaplan-Meier method. Differences in survival based on risk factors were tested using a log-rank test.
RESULTS
Median total radiotherapy dose was 60 Gy (range, 52.5 to 63.6 Gy). Four patients received concurrent weekly chemotherapy with cisplatin. Among 10 patients who underwent surgery with neck dissection, 7 received modified radical neck dissection. With a median follow-up time of 38 months (range, 24 to 105 months), 4-year rates were 86% for LRFFS, 51% for DFFS, 46% for PFS, and 93% for OS. Local failure was observed in 2 patients (13%), and distant failure was observed in 7 (47%). The lung was the most common involved site of distant metastasis.
CONCLUSION
Surgery and postoperative radiotherapy in SDC patients resulted in good local control, but high distant metastasis remained a major challenge.

Keyword

Salivary ducts; Radiotherapy; Carcinoma

MeSH Terms

Cisplatin
Disease-Free Survival
Drug Therapy
Follow-Up Studies
Humans
Lung
Male
Neck Dissection
Neoplasm Metastasis
Parotid Gland
Radiotherapy*
Radiotherapy, Conformal
Radiotherapy, Intensity-Modulated
Risk Factors
Salivary Ducts*
Cisplatin